Advanced search
Publication Cover
Future Medicinal Chemistry Volume 2, 2010 - Issue 10
Submit an article Journal homepage
12,815
Views
0
CrossRef citations to date
0
Altmetric
Review

Protein Tyrosine Phosphatases as Drug Targets: Strategies and Challenges of Inhibitor Development

Alastair J BarrUniversity of Oxford, Structural Genomics Consortium, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford, OX3 7DQ, UKCorrespondence[email protected]
View further author information
Pages 1563-1576 | Published online: 13 Oct 2010

Bibliography

  • Soulsby M , BennettAM. Physiological signaling specificity by protein tyrosine phosphatases.Physiology (Bethesda)24, 281–289 (2009).
  • Manning G , WhyteDB, MartinezR, HunterT, SudarsanamS. The protein kinase complement of the human genome.Science298(5600), 1912–1934 (2002).
  • Alonso A , SasinJ, BottiniNet al. Protein tyrosine phosphatases in the human genome. Cell 117(6), 699–711 (2004).
  • Shi Y . Serine/threonine phosphatases: mechanism through structure.Cell139(3), 468–484 (2009).
  • Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature447(7145), 661–678 (2007).
  • Tautz L , PellecchiaM, MustelinT. Targeting the PTPome in human disease.Expert Opin. Ther. Targets10(1), 157–177 (2006).
  • Easty D , GallagherW, BennettDC. Protein tyrosine phosphatases, new targets for cancer therapy.Curr. Cancer Drug Targets6(6), 519–532 (2006).
  • Ostman A , HellbergC, BohmerFD. Protein-tyrosine phosphatases and cancer.Nat. Rev. Cancer, 6(4), 307–320 (2006).
  • Wang Z , ShenD, ParsonsDWet al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science304(5674), 1164–1166 (2004).
  • Bottini N , MusumeciL, AlonsoAet al. A functional variant of lymphoid tyrosine phosphatase is associated with Type I diabetes. Nat. Genet. 36(4), 337–338 (2004).
  • Stanford SM , MustelinTM, BottiniN. Lymphoid tyrosine phosphatase and autoimmunity: human genetics rediscovers tyrosine phosphatases.Semin. Immunopathol.32(2), 127–136 (2010).
  • Muise AM , WaltersT, WineEet al. Protein-tyrosine phosphatase sigma is associated with ulcerative colitis. Curr. Biol. 17(14), 1212–1218 (2007).
  • Elchebly M , PayetteP, MichaliszynEet al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283(5407), 1544–1548 (1999).
  • Blaskovich MA . Drug discovery and protein tyrosine phosphatases.Curr. Med. Chem.16(17), 2095–2176 (2009).
  • Bentires-Alj M , NeelBG. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer.Cancer Res.67(6), 2420–2424 (2007).
  • Julien SG , DubeN, ReadMet al. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nature Genet. 39(3), 338–346 (2007).
  • Tonks NK , MuthuswamySK. A brake becomes an accelerator: PTP1B – a new therapeutic target for breast cancer.Cancer Cell11(3), 214–216 (2007).
  • Liu G . Technology evaluation: ISIS-113715, Isis.Curr. Opin. Mol. Ther.6(3), 331–336 (2004).
  • Zinker BA , RondinoneCM, TrevillyanJMet al. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc. Natl Acad. Sci. USA 99(17), 11357–11362 (2002).
  • Czernilofsky AP , LevinsonAD, VarmusHE, BishopJM, TischerE, GoodmanHM. Nucleotide sequence of an avian sarcoma virus oncogene (src) and proposed amino acid sequence for gene product. Nature287(5779), 198–203 (1980).
  • Guan KL , HaunRS, WatsonSJ, GeahlenRL, DixonJE. Cloning and expression of a protein-tyrosine-phosphatase.Proc. Natl Acad. Sci.USA87(4), 1501–1505 (1990).
  • Iversen LF , MollerKB, PedersenAKet al. Structure determination of T cell protein-tyrosine phosphatase. J. Biol. Chem. 277(22), 19982–19990 (2002).
  • You-Ten KE , MuiseES, ItieAet al. Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J. Exp. Med. 186(5), 683–693 (1997).
  • Hassan SW , DoodyKM, HardyS, UetaniN, CournoyerD, TremblayML. Increased susceptibility to dextran sulfate sodium induced colitis in the T cell protein tyrosine phosphatase heterozygous mouse.PloS ONE5(1), e8868 (2010).
  • Tautz L , MustelinT. Strategies for developing protein tyrosine phosphatase inhibitors.Methods42(3), 250–260 (2007).
  • McGovern SL , CaselliE, GrigorieffN, ShoichetBK. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.J. Med. Chem.45(8), 1712–1722 (2002).
  • Guertin KR , SettiL, QiLet al. Identification of a novel class of orally active pyrimido[5,4–3][1,2,4]triazine-5,7-diamine-based hypoglycemic agents with protein tyrosine phosphatase inhibitory activity. Bioorg. Med. Chem. Lett. 13(17), 2895–2898 (2003).
  • Wang Q , DubeD, FriesenRWet al. Catalytic inactivation of protein tyrosine phosphatase CD45 and protein tyrosine phosphatase 1B by polyaromatic quinones. Biochemistry 43(14), 4294–4303 (2004).
  • Montalibet J , SkoreyKI, KennedyBP. Protein tyrosine phosphatase: enzymatic assays.Methods35(1), 2–8 (2005).
  • Perrin D , FremauxC, BessonD, SauerWH, ScheerA. A microfluidics-based mobility shift assay to discover new tyrosine phosphatase inhibitors. .J Biomol. Screen11(8), 996–1004 (2006).
  • Byon JC , KusariAB, KusariJ. Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction.Mol. Cell. Biochem.182(1–2), 101–108 (1998).
  • Walchli S , CurchodML, GobertRP, ArkinstallS, Hooft van Huijsduijnen R. Identification of tyrosine phosphatases that dephosphorylate the insulin receptor. A brute force approach based on ‘substrate-trapping’ mutants. J. Biol. Chem.275(13), 9792–9796 (2000).
  • Salmeen A , AndersenJN, MyersMP, TonksNK, BarfordD. Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B.Mol. Cell6(6), 1401–1412 (2000).
  • Bence KK , DelibegovicM, XueBet al. Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat. Med. 12(8), 917–924 (2006).
  • Delibegovic M , BenceKK, ModyNet al. Improved glucose homeostasis in mice with muscle-specific deletion of protein-tyrosine phosphatase 1B. Mol. Cell. Biol. 27(21), 7727–7734 (2007).
  • Puius YA , ZhaoY, SullivanM, LawrenceDS, AlmoSC, ZhangZY. Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design.Proc. Natl Acad. Sci. USA94(25), 13420–13425 (1997).
  • Andersen HS , IversenLF, JeppesenCBet al. 2-(Oxalylamino)-benzoic acid is a general, competitive inhibitor of protein-tyrosine phosphatases. J. Biol. Chem. 275(10), 7101–7108 (2000).
  • Burke TR Jr. Design and synthesis of phosphonodifluoromethyl phenylalanine (F2Pmp): a useful phosphotyrosyl mimetic. Curr. Top. Med. Chem.6(14), 1465–1471 (2006).
  • Shen K , KengYF, WuL, GuoXL, LawrenceDS, ZhangZY. Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure.J. Biol. Chem.276(50), 47311–47319 (2001).
  • Sun JP , FedorovAA, LeeSYet al. Crystal structure of PTP1B complexed with a potent and selective bidentate inhibitor. J. Biol. Chem. 278(14), 12406–12414 (2003).
  • Boutselis IG , YuX, ZhangZY, BorchRF. Synthesis and cell-based activity of a potent and selective protein tyrosine phosphatase 1B inhibitor prodrug.J. Med. Chem.50(4), 856–864 (2007).
  • Scapin G , PatelSB, BeckerJWet al. The tructural basis for the selectivity of benzotriazole inhibitors of PTP1B. Biochemistry 42(39), 11451–11459 (2003).
  • Combs AP . Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer.J. Med. Chem.53(6), 2333–2344 (2010).
  • Ala PJ , GonnevilleL, HillmanMet al. Structural insights into the design of nonpeptidic isothiazolidinone-containing inhibitors of protein-tyrosine phosphatase 1B. J. Biol. Chem. 281(49), 38013–38021 (2006).
  • Combs AP , ZhuW, CrawleyMLet al. Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic. J. Med Chem. 49(13), 3774–3789 (2006).
  • Douty B , WaylandB, AlaPJet al. Isothiazolidinone inhibitors of PTP1B containing imidazoles and imidazolines. Bioorg. Med. Chem. Lett. 18(1), 66–71 (2008).
  • Szczepankiewicz BG , LiuG, HajdukPJet al. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J. Am. Chem. Soc. 125(14), 4087–4096 (2003).
  • Liu G , XinZ, LiangHet al. Selective protein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyrosine binding site with noncarboxylic acid-containing ligands. J. Med. Chem. 46(16), 3437–3440 (2003).
  • Liu G , XinZ, PeiZet al. Fragment screening and assembly: a highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor. J. Med. Chem. 46(20), 4232–4235 (2003).
  • Hartshorn MJ , MurrayCW, CleasbyA, FredericksonM, TickleIJ, JhotiH. Fragment-based lead discovery using x-ray crystallography.J. Med. Chem.48(2), 403–413 (2005).
  • Doman TN , McGovernSL, WitherbeeBJet al. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J. Med. Chem. 45(11), 2213–2221 (2002).
  • Malamas MS , SredyJ, MoxhamCet al. Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties. J. Med. Chem. 43(7), 1293–1310 (2000).
  • Erbe DV , WangS, ZhangYLet al. Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms. Mol. Pharm. 67(1), 69–77 (2005).
  • Kumar A , AhmadP, MauryaRA, SinghAB, SrivastavaAK. Novel 2-aryl-naphtho[1,2-d]oxazole derivatives as potential PTP-1B inhibitors showing antihyperglycemic activities.Eur. J. Med. Chem.44(1), 109–116 (2009).
  • Wilson DP , WanZK, XuWXet al. Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site. J. Med. Chem. 50(19), 4681–4698 (2007).
  • Ye D , ZhangY, WangFet al. Novel thiophene derivatives as PTP1B inhibitors with selectivity and cellular activity. Bioorg. Med. Chem. 18(5), 1773–1782 (2010).
  • Fukuda S , OhtaT, SakataSet al. Pharmacological profiles of a novel protein tyrosine phosphatase 1B inhibitor, JTT-551. Diabetes, Obes. Metab. 12(4), 299–306 (2010).
  • Colca JR . Discontinued drug in 2007: renal, endocrine and metabolic drugs.Expert Opin Investig. Drugs, 17(11), 1641–1650 (2008).
  • Asante-Appiah E , PatelS, DespontsCet al. Conformation-assisted inhibition of protein-tyrosine phosphatase-1B elicits inhibitor selectivity over T-cell protein-tyrosine phosphatase. J. Biol. Chem. 281(12), 8010–8015 (2006).
  • Wiesmann C , BarrKJ, KungJet al. Allosteric inhibition of protein tyrosine phosphatase 1B. Nat. Struct. Mol. Biol. 11(8), 730–737 (2004).
  • Peng H , XieW, OtternessDMet al. Syntheses and biological activities of a novel group of steroidal derived inhibitors for human Cdc25A protein phosphatase. J. Med. Chem. 44(5), 834–848 (2001).
  • Lantz KA , HartSG, PlaneySLet al. Inhibition of PTP1B by trodusquemine (MSI-1436) causes fat-specific weight loss in diet-induced obese mice. Obesity (Silver Spring) 18(8), 1516–1523 (2010).
  • Swarbrick MM , HavelPJ, LevinAAet al. Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys. Endocrinology 150(4), 1670–1679 (2009).
  • Pao LI , BadourK, SiminovitchKA, NeelBG. Nonreceptor protein-tyrosine phosphatases in immune cell signaling.Annu. Rev. Immunol.25, 473–523 (2007).
  • Hof P , PluskeyS, Dhe-PaganonS, EckMJ, ShoelsonSE. Crystal structure of the tyrosine phosphatase SHP-2.Cell92(4), 441–450 (1998).
  • Chan G , KalaitzidisD, NeelBG. The tyrosine phosphatase Shp2 (PTPN11) in cancer.Cancer Metastasis Rev.27(2), 179–192 (2008).
  • Tartaglia M , NiemeyerCM, FragaleAet al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet. 34(2), 148–150 (2003).
  • Xu R , YuY, ZhengSet al. Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia. Blood 106(9), 3142–3149 (2005).
  • Zhou X , CoadJ, DucatmanB, AgazieYM. SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis.Histopathology53(4), 389–402 (2008).
  • Hatakeyama M . Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat. Rev. Cancer4(9), 688–694 (2004).
  • Xu R . SHP2, a novel oncogenic tyrosine phosphatase and potential therapeutic target for human leukemia.Cell Res.17(4), 295–297 (2007).
  • Shultz LD , RajanTV, GreinerDL. Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency.Trends Biotechnol.15(8), 302–307 (1997).
  • Chen L , SungSS, YipMLet al. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol. Pharm. 70(2), 562–570 (2006).
  • Lawrence HR , PiredduR, ChenLet al. Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) based on oxindole scaffolds. J. Med. Chem. 51(16), 4948–4956 (2008).
  • Noren-Muller A , Reis-CorreaI Jr, Prinz H et al. Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. Proc. Natl Acad. Sci. USA103(28), 10606–10611 (2006).
  • Hellmuth K , GrosskopfS, LumCTet al. Specific inhibitors of the protein tyrosine phosphatase SHP2 identified by high-throughput docking. Proc. Natl Acad. Sci. USA 105(20), 7275–7280 (2008).
  • Geronikaki A , EleftheriouP, ViciniP, AlamI, DixitA, SaxenaAK. 2-thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action.J. Med. Chem.51(17), 5221–5228 (2008).
  • Zhang X , HeY, LiuSet al. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). J. Med. Chem. 53(6), 2482–2493).
  • Pathak MK , YiT. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines.J. Immunol.167(6), 3391–3397 (2001).
  • Kundu S , FanK, CaoMet al. Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents. J. Immunol. 184(11), 6529–6536 (2010).
  • Vang T , CongiaM, MacisMDet al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet. 37(12), 1317–1319 (2005).
  • Xie Y , LiuY, GongGet al. Discovery of a novel submicromolar inhibitor of the lymphoid specific tyrosine phosphatase. Bioorg. Med. Chem. Lett. 18(9), 2840–2844 (2008).
  • Yu X , SunJP, HeYet al. Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases. Proc. Natl Acad. Sci. USA 104(50), 19767–19772 (2007).
  • Karver MR , KrishnamurthyD, BottiniN, BarriosAM. Gold(I) phosphine mediated selective inhibition of lymphoid tyrosine phosphatase.J. Inorg. Biochem.104(3), 268–273 (2010).
  • Barr AJ , UgochukwuE, LeeWHet al. Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 136(2), 352–363 (2009).
  • Wu S , BottiniM, RickertRC, MustelinT, TautzL. In silico screening for PTPN22 inhibitors: active hits from an inactive phosphatase conformation. ChemMedChem4(3), 440–444 (2009).
  • Barr AJ , KnappS. MAPK-specific tyrosine phosphatases: new targets for drug discovery?.Trends Pharmacol Sci.27(10), 525–530 (2006).
  • Braithwaite SP , PaulS, NairnAC, LombrosoPJ. Synaptic plasticity: one STEP at a time.Trends Neurosci.29(8), 452–458 (2006).
  • Eswaran J , von KriesJP, MarsdenBet al. Crystal structures and inhibitor identification for PTPN5, PTPRR and PTPN7: a family of human MAPK-specific protein tyrosine phosphatases. Biochem. J.395(3), 483–491 (2006).
  • Senis YA , TomlinsonMG, EllisonSet al. The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis. Blood 113(20), 4942–4954 (2009).
  • Takahashi T , TakahashiK, MernaughRL, TsuboiN, LiuH, DanielTO. A monoclonal antibody against CD148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell growth and angiogenesis.Blood108(4), 1234–1242 (2006).
  • Kahn SE , HullRL, UtzschneiderKM. Mechanisms linking obesity to insulin resistance and Type II diabetes.Nature444(7121), 840–846 (2006).
  • Delibegovic M , ZimmerD, KauffmanCet al. Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes 58(3), 590–599 (2009).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.